In early and advanced Parkinson’ s disease, efficacy of SIFROL in the controlled clinical trials was maintained for approximately six months.
Varases ja kaugelearenenud Parkinsoni tõve staadiumis säilis SIFROL' i efektiivsus kontrollitud kliinilises uuringus umbes 6 kuud.